Stock prices for embryonic stem cell research companies took a hit when the U.S. Senate failed to pass a bill to overturn President Bush’s stem cell funding policy by a veto proof margin. Worcester, MA’s, Advanced Cell Technology—which opened an office in California to try and take advantage of the cornicopia of Proposition 71 money—lost value, as did California’s Geron. Some adult stem cell companies also lost ground, but others gained.
Well, the market doesn’t lie: A big part of the drive to overturn Bush’s policy is pure corporate welfare pork. Sooweeee!
YOU MIGHT ALSO LIKE
Deliver Us from Evil
In a recent New York Times article entitled “Freedom With a Side of Guilt: How Food Delivery…
Natural Law Needs Revelation
Natural law theory teaches that God embedded a teleological moral order in the world, such that things…
Letters
Glenn C. Loury makes several points with which I can’t possibly disagree (“Tucker and the Right,” January…
